Introduction {#Sec1}
============

Nowadays, revascularization by percutaneous coronary intervention (PCI) is increasing in patients with coronary artery disease (CAD). This drastic increase might be due to several advantages of this invasive procedure compared to open-heart surgery \[[@CR1]\]. Although dual antiplatelet therapy (DAPT) is often prescribed in patients with stable CAD without revascularization, this drug regimen is often indicated after implantation of drug-eluting stents (DES) to reduce and prevent stent thrombosis, re-infarction, and even stroke which might lead to severe unwanted health conditions \[[@CR2]\]. However, as a result of other health issues, there is a small subgroup of patients who can either use aspirin (ASA) or clopidogrel monotherapy, but not both \[[@CR3], [@CR4]\].

Although ASA is the mainstay of treatment for the prevention of recurrent ischemic stroke \[[@CR5]\], the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks \[[@CR6]\].

Therefore, through this analysis, we aimed to systematically compare ASA versus clopidogrel monotherapy for the treatment of patients with stable CAD.

Methods {#Sec2}
=======

Databases {#Sec3}
---------

The following electronic databases were searched:Cochrane CentralExcerpta Medica database (EMBASE) ([www.sciencedirect.com](http://www.sciencedirect.com))Medical Literature Analysis and Retrieval System Online (MEDLINE)Google Scholar

Search Terms {#Sec4}
------------

A broad search was carried out using the aforementioned online databases. The search terms included:Aspirin versus clopidogrel monotherapy and coronary artery diseaseAspirin versus clopidogrel and percutaneous coronary interventionAspirin, clopidogrel, PCIAspirin, clopidogrel, cardiovascular diseaseAspirin monotherapy, PCIClopidogrel monotherapy, PCI

These terms were searched and English publications were retrieved.

Inclusion and Exclusion Criteria {#Sec5}
--------------------------------

Studies were included if:They compared the treatment outcomes with ASA versus clopidogrel monotherapy in patients with CAD.They reported the relevant adverse clinical (cardiovascular and bleeding) outcomes.

Studies were excluded if:They were reviews, case studies, or letters to editors.They did not compare treatment outcomes with ASA versus clopidogrel monotherapy in patients with CAD.They compared ASA monotherapy versus DAPT in patients with CAD.They did not report the relevant adverse clinical outcomes.They were duplicated studies.

Outcomes Assessed and Follow-up Time Periods {#Sec6}
--------------------------------------------

The outcomes which were assessed are listed in Table [1](#Tab1){ref-type="table"}. They included:Table 1Outcomes which were reportedStudiesAdverse outcomesFollow-up periodBerger (2008) \[[@CR11]\]Death2 yearsLemesle (2016) \[[@CR12]\]Composite endpoints, all-cause death, cardiac death, MI, stroke, BARC type ≥ 3 bleeding2 yearsPark (2016) \[[@CR13]\]Composite endpoints, all-cause death, cardiac death, MI, stroke, BARC type ≥ 3 bleeding3 years*MI* myocardial infarction, *BARC* bleeding according to the Bleeding Academic Research Consortium; composite outcomes include: cardiovascular death, MI and strokeComposite outcomes: a combination of cardiovascular death, myocardial infarction (MI), and strokeAll-cause mortalityCardiac deathMIStrokeBleeding defined by the Bleeding Academic Research Consortium (BARC) grade 3 or above \[[@CR7]\]

This analysis had a mean follow-up period ranging from 2 to 3 years.

Data Extraction and Quality Assessment {#Sec7}
--------------------------------------

The following data were extracted by all three authors:Number of participants in the ASA monotherapy groupNumber of participants in the clopidogrel monotherapy groupType of studyAdverse clinical (cardiovascular and bleeding) outcomes along with the follow-up periodsBaseline featuresPatients' enrollment time period for studyMethodological quality of the studies

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline was followed \[[@CR8]\]. The methodological quality of the studies was assessed by the:Cochrane Collaboration for the randomized controlled trials \[[@CR9]\]Newcastle--Ottawa Scale (NOS) for the observational studies \[[@CR10]\]

Statistical Analysis {#Sec8}
--------------------

The latest version of RevMan software (version 5.3) was used as the statistical tool for the data analysis. Odds ratios (OR) and 95% confidence intervals (CI) were generated to interpret the data.

Heterogeneity was assessed by the:*Q* statistical test (*P* ≤ 0.05 was considered statistically significant)*I*^2^ statistical test (the higher the value of *I*^2^, the greater the heterogeneity)

A fixed (*I*^2^ \< 50%) effects model or a random (*I*^2^ \> 50%) effects model was used on the basis of the *I*^2^ values which were obtained.

Sensitivity analysis was carried out by excluding each study turn by turn, and observing any significant difference in the results which were obtained.

Publication bias was observed through funnel plots.

Compliance with Ethics Guidelines {#Sec9}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec10}
=======

Searched Outcomes {#Sec11}
-----------------

Electronic search resulted in 284 articles. After careful assessment of the abstracts, 271 articles were eliminated because they were not related to the scope of this research. Thirteen full-text articles were assessed for eligibility. Further eliminations were due to the following reasons:They compared ASA versus DAPT (8).They were duplicated studies (2).

Finally, only three articles \[[@CR11]--[@CR13]\] were selected for this analysis as shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of study selection

General Features of the Studies {#Sec12}
-------------------------------

Two studies were observational cohorts, whereas one study was a sub-study of a randomized controlled trial. Table [2](#Tab2){ref-type="table"} lists the general features of the studies which were included in this analysis.Table 2General features of the studiesStudiesNo. of patients treated with aspirin monotherapy (*n*)No. of patients treated with clopidogrel monotherapy (*n*)Year of patients' enrollmentType of studyBerger (2008) \[[@CR11]\]10001000--RCTLemesle (2016) \[[@CR12]\]20257732010--2011OSPark (2016) \[[@CR13]\]24727712003--2010OSTotal no. of patients (*n*)54972544*RCT* randomized controlled trial, *OS* observational study

A total of 5497 patients were treated with ASA monotherapy, whereas 2544 patients were treated with clopidogrel monotherapy. Patients' enrollment period ranged from the year 2003 to 2011 as shown in Table [2](#Tab2){ref-type="table"}.

After careful assessment of the methodological quality of each study, a moderate risk of bias was expected with the randomized trial, whereas a low bias risk was observed in both of the observational studies.

Baseline Features of Participants {#Sec13}
---------------------------------

Table [3](#Tab3){ref-type="table"} lists the baseline features of the participants. Mean age varied from 62 to 68.2 years. Most of the participants were male patients with comorbidities such as hypertension, dyslipidemia, diabetes mellitus, and smoking. According to the baseline features, there were no significant differences between those patients who were treated by ASA or clopidogrel monotherapy.Table 3Baseline features of the participantsStudiesAge (years)Men (%)HT (%)Ds (%)DM (%)Cs (%)ASA/CLPASA/CLPASA/CLPASA/CLPASA/CLPASA/CLPBerger (2008) \[[@CR11]\]62.5/62.572.0/72.051.0/52.041.0/41.020.0/20.030.0/29.0Lemesle (2016) \[[@CR12]\]66.5/68.277.9/78.456.0/64.7--28.3/32.610.9/12.1Park (2016) \[[@CR13]\]62.0/64.073.3/73.953.2/64.528.5/33.533.7/42.217.4/22.6*ASA* aspirin, *CLP* clopidogrel, *HT* hypertension, *Ds* dyslipidemia, *DM* diabetes mellitus, *Cs* current smoking

Main Results of This Analysis {#Sec14}
-----------------------------

This analysis had a follow-up time period of 2--3 years and the results are listed in Table [4](#Tab4){ref-type="table"}.Table 4Results of this analysisOutcomesOR with 95% CI*P* value*I*^2^ (%)Statistical model usedComposite endpoints0.99 \[0.47--2.10\]0.9883Random effectsAll-cause death1.05 \[0.82--1.33\]0.7113Fixed effectsCardiac death0.89 \[0.17--4.74\]0.8988Random effectsMyocardial infarction0.84 \[0.52--1.36\]0.480Fixed effectsStroke1.26 \[0.39--4.06\]0.7080Random effectsBARC-defined bleeding1.28 \[0.78--2.12\]0.3310Fixed effects*OR* odds ratios, *CI* confidence intervals, *BARC* bleeding defined according to the Bleeding Academic Research Consortium

No significant difference was observed in composite endpoints (cardiovascular death, MI, and stroke) (OR 0.99, 95% CI 0.47--2.10; *P* = 0.98), all-cause mortality (OR 1.05, 95% CI 0.82--1.33; *P* = 0.71), cardiac death (OR 0.89, 95% CI 0.17--4.74;*P* = 0.89), MI (OR 0.84, 95% CI 0.52--1.36; *P* = 0.48), stroke (OR 1.26, 95% CI 0.39--4.06; *P* = 0.70), and BARC-defined bleeding grade 3 or above (OR 1.28, 95% CI 0.78--2.12; *P* = 0.33) as shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.Fig. 2Adverse clinical outcomes which were observed with aspirin versus clopidogrel monotherapy (part 1)Fig. 3Adverse clinical outcomes which were observed with aspirin versus clopidogrel monotherapy (part 2)

Sensitivity Analysis {#Sec15}
--------------------

Consistent results were obtained when sensitivity analyses were carried out by eliminating each study one by one and then observing any significant difference. On the basis of a visual inspection of the funnel plot (Fig. [4](#Fig4){ref-type="fig"}), there was little to moderate evidence of publication bias across the studies which were involved in the assessment of the different clinical outcomes.Fig. 4Funnel plot showing publication bias

Discussion {#Sec16}
==========

Guidelines recommend treatment with DAPT (aspirin + clopidogrel) following coronary angioplasty with DES. Normally, clopidogrel is used for only 6 months to 1 year, whereas aspirin is continually used throughout. However, in CAD patients with high risk of bleeding, the use of clopidogrel is a relative contraindication. Therefore, only ASA is used as a single antiplatelet agent. On the other hand, in patients with chronic gastritis, especially non-steroidal anti-inflammatory drug-induced gastritis, ASA is often avoided, and therefore, those patients rely only on clopidogrel as a single antiplatelet drug.

The results of the current analysis showed no significant difference in clinical outcomes with ASA or clopidogrel monotherapy. All-cause mortality, cardiac death, MI, stroke, and bleeding defined by the Bleeding Academic Research Consortium were not significantly different. A recent meta-analysis even showed that a high dose of ASA following coronary angioplasty was not associated with significantly higher cardiovascular death/MI/stroke or any major bleeding, implying that ASA alone might be safe to use \[[@CR14]\]. In addition, a randomized open-label Korean study involving 60 healthy participants showed ASA and clopidogrel to have similar absorption profiles implying that both treatments were equally tolerated \[[@CR15]\].

A CAPRIE-based cost-effectiveness model for Greece investigating ASA versus clopidogrel in patients with atherosclerosis showed the latter to be cost effective as a secondary prevention of thrombotic events in Greek patients, implying that a single antiplatelet agent would also work well instead of a DAPT regimen \[[@CR16]\].

Several studies were based on the comparison of DAPT versus antiplatelet drug therapy. In the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial, the authors showed no difference in cardiovascular or bleeding outcomes with the use of either DAPT or aspirin monotherapy \[[@CR17]\]. It should be noted that the cardiovascular outcomes included non-fatal MI, all-cause mortality, and stroke, whereas the bleeding outcomes consisted of blood transfusion, major bleeding, and hospitalization for bleeding events during a long-term period following coronary artery bypass surgery.

The Management of ATherothrombosis with Clopidogrel in High-risk patients (MATCH) trial showed that the addition of ASA to clopidogrel in high-risk patients who were recently affected by thrombotic events resulted in a higher risk of life-threatening and major bleeding, thus favoring the use of clopidogrel as the only single antiplatelet agent \[[@CR18]\]. In addition, when the use of clopidogrel was compared to that of ASA monotherapy following 12 months DAPT use, clopidogrel monotherapy was cost effective in an analysis from a China payer's perspective \[[@CR19]\]. Also a recent study showed clopidogrel monotherapy to be more beneficial to smokers with atherosclerotic diseases \[[@CR20]\].

Although the current analysis showed ASA and clopidogrel monotherapy to be equally tolerated, other larger trials should confirm this hypothesis. Furthermore, other new results will be obtained with the upcoming SMART-CHOICE trial which will assess DAPT versus clopidogrel monotherapy following PCI \[[@CR21]\].

Finally, a limitation of this analysis was that the total number of participants was not sufficient to reach a significant conclusion. In addition, other bleeding outcomes and stent thrombosis were unfortunately not assessed because they were not reported in these studies. Finally, we should not completely depend on this new hypothesis which has been generated with limited data. Future results and conclusions generated by larger well-conducted clinical trials should be awaited.

Conclusions {#Sec17}
===========

This analysis did not show any significant difference in all-cause mortality, cardiac death, MI, stroke, and BARC-defined bleeding grade 3 or above among CAD patients who were treated with ASA or clopidogrel monotherapy. However, this hypothesis should be confirmed in other major trials.
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